. "Appendix A: Methodology." The Unequal Burden of Cancer: An Assessment of NIH Research and Programs for Ethnic Minorities and the Medically Underserved. Washington, DC: The National Academies Press, 1999.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Information to minority and medically underserved communities and their providers.
Information on publications resulting from NIH grants for research on cancer among minorities and medically underserved populations.
Information on research grants related to cancer survivorship and supported by the NCI.
Information on ongoing activities of the Office of Cancer Survivorship.
Additional Information Resources
Computer Retrieval of Information Scientific Projects
To further assist the committee in its review of the NCI and NIH research agenda the Institute of Medicine (IOM) staff conducted a search of the Computer Retrieval of Information on Scientific Projects (CRISP) database. The CRISP database contains information on federally funded research, including grants, contracts, and cooperative agreements conducted primarily by investigators at universities, hospitals, and other research institutions. Projects listed in the CRISP database are funded by a number of US Public Health Services agencies including NIH. This database contains information on special projects, investigators, scientific concepts, and emerging trends. The CRISP database is updated weekly.
The IOM staff search was conducted for projects funded in 1997 only. Specific search terms used included "NIH" or "NCI," "R01," "CA'' for cancer, and the wildcard "minority*." There is no global term in the CRISP database for "underserved" or "medically underserved."
The committee held a public meeting on June 11–12, 1998, in Washington, D.C. The purpose of this meeting was to provide an opportunity for cancer advocacy groups and community-based health organizations to present their views on the responsiveness of NIH to their concerns and input into cancer research studies. The committee also heard testimony from invited NIH representatives. A copy of the agenda for this meeting is located in Appendix D.